Spots Global Cancer Trial Database for Follow-up After Metastasectomy in Patients With Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Follow-up After Metastasectomy in Patients With Kidney Cancer
Official Title: A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma
Study ID: NCT00918775
Conditions
Study Description
Brief Summary: This phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.
Detailed Description: PRIMARY OBJECTIVES: I. To assess the 24-week progression free/relapse free survival rate in patients undergoing metastasectomy for metastatic renal cell carcinoma (mRCC). SECONDARY OBJECTIVES: I. To evaluate progression free survival (PFS), relapse free survival (RFS) and overall survival (OS) in patients undergoing metastasectomy. II. To evaluate tissue determinants predictive for resectability, PFS and OS in patients undergoing metastasectomy. OUTLINE: After metastasectomy, patients are followed up every 6 months for up to 5 years.
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Eric Jonasch
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
